Cytokines in Inflammatory Bowel Disease

References

• Jewell D P, Snook JA. Immunology of ulcerative colitis and Crohn's disease. Inflammatory bowel disease, RN Allan, MRB Keighley, J Alexander-Williams, CF Hawkins. Churchill Livingstone, London 1990; 127–46
   Google Scholar
• Brynskov J, Freund L, Rasmussen S N. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active Crohn's disease. N. Engl J Med 1989; 321: 845–50
   PubMed Web of Science ®Google Scholar
• Brynskov J, Freund L, Rasmussen S N. Final report on a placebo-controlled, double blind, randomised, multicentre trial of cyclosporin treatment in active Crohn's disease. Scand J Gastroenterol 1991; 26: 689–95
   PubMed Web of Science ®Google Scholar
• Markowitz J, Daum F. Immunology of inflammatory bowel disease: summary of the proceedings of the subcommittee on immunosuppressive use in IBD. J Pediatr Gastroenterol Nutr 1991; 12: 411–23
   PubMedGoogle Scholar
• Bentzen K. Cellular and molecular processes underlying immunoinflammation. Clinical impact of the monitoring of allergic inflammation, P Matsson, S Ahlstedt, P Venge, J Thorell. Academic Press, London 1991; 187–200
   Google Scholar
• Bendtzen K. Immune hormones (cytokines); pathogenic role in autoimmune rheumatic diseases and endocrine diseases. Autoimmunity 1989; 2: 177–89
   PubMed Web of Science ®Google Scholar
• Miura M, Hiwatshi N. Cytokine production in inflammatory bowel disease. J Clin Lab Immunol 1985; 33: 232–44
   Google Scholar
• Satsangi J, Wolstencroft R A, Cason J, Ainley C C, Dumonde D C, Thompson R PH. Interleukin 1 in Crohn's disease. Clin Exp Immunol 1987; 67: 594–605
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Quinn D G, Tobin A, Whelan C A, O'Morain C. Production of interleukin 1 by highly purified monocytes in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1991; 3: 45–9
   Web of Science ®Google Scholar
• Hodgson H JF, Mazlam MZ. Cytokines-are they different in ulcerative colitis and Crohn's disease. Inflammatory bowel disease. Progress in basic research and clinical implications, H Goebell, H Malchow, K Ewe, C Koelbel. Kluwer Academic Publishers, Dordrecht 1991; 161–8
   Google Scholar
• Mahida Y R, Wu K, Jewell DP. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis or Crohn's disease. Gut 1989; 30: 835–8
   PubMed Web of Science ®Google Scholar
• Brynskov J, Tvede N, Vilien M, Andersen C B, Bentzen K. Increased concentrations of interleukin 1β, interleukin 2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease. Gut 1992; 33: 55–8
   PubMed Web of Science ®Google Scholar
• Ligumski M, Simon P L, Karmeli F, Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease: enhanced production during active disease. Gut 1990; 31: 6869
   Google Scholar
• Rachmilewitz D, Simon P L, Schwartz L W, Griswald D E, Fondacaro J D, Wasserman MA. Inflammatory mediators of experimental colitis in rats. Gatroenterology 1989; 97: 32637
   Google Scholar
• Radema S A, VanDeventer S JH, Cerami A. Interleukin 18 is expressed predominantly by enterocytes in experimental colitis. Gastroenterology 1991; 100: 118–8
   Google Scholar
• Brynskov J, Hansen M B, Reimert C, Bentzen K. Inhibitor of interleukin lα and interleukin lβ-induced T-cell activation in serum of patients with active Crohn's disease. Dig Dis Sci 1991; 36: 737–42
   PubMedGoogle Scholar
• Larrick JW. Native interleukin 1 inhibitors. Immunol Today 1989; 10: 61–66
   PubMedGoogle Scholar
• Bendtzen K, Svenson M, JóSsson V, Hippe E. Autoantibodies to cytokines-friends or foes. Immunol Today 1990; 11: 167–9
   PubMedGoogle Scholar
• Cannon J G, Dinarello CA. Increased plasma interleukin 1 activity in women after ovulation. Science 1985; 227: 1247–9
   PubMed Web of Science ®Google Scholar
• Dinarello C A, Rosenwasser L J, Wolf SM. Demonstration of a circulating suppressor factor of thymocyte proliferation during endotoxin fever in humans. J Immunol 1981; 127: 2517–19
   PubMed Web of Science ®Google Scholar
• Liao Z, Grimshaw R S, Rosenstreich DL. Identification of a specific interleukin 1 inhibitor in the urine of febrile patients. J Exp Med 1984; 159: 12636
   Google Scholar
• Seckinger P, Williamson K, Balavoine J F. A urine inhibitor of interleukin 1 activity affects both interleukin lα and 1β but not tumour necrosis factor. J Immunol 1987; 139: 1541–5
   PubMed Web of Science ®Google Scholar
• Seckinger P, Lowenthal J W, Williamson K, Dayer J M, Mac-Donald HR. A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol 1987; 139: 15469
   Google Scholar
• Arend WP. Interleukin 1 receptor antagonists. A new member of the interleukin 1 family. J Clin Invest 1991; 88: 1445–51
   PubMed Web of Science ®Google Scholar
• Dinarello C A, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991; 12: 404–10
   PubMedGoogle Scholar
• Eisenberg S P, Brewer M T, Verderber E, Heimdal P, Brandhuber B J, Thompson RC. Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family: evolution of a cytokine control mechanism. Proc Natl Acad Sci 1991; 88: 5232–6
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen J H, Dinarello C A, Svenson M. Human PI 7 interleukin 1 is cytotoxic for pancreatic islets of Langerhans. Science 1986; 232: 1545–7
   PubMed Web of Science ®Google Scholar
• Onozaki K, Matsushima K, Aggarwal B B, Oppenheim JJ. Human interleukin 1 is cytocidal factor for several tumor cell lines. J Immunol 1985; 135: 3962–8
   PubMed Web of Science ®Google Scholar
• Pettipher E R, Henderson B, Higgs G A, Moncada S. Arthritogenic activity of interleukin 1 in leucopaenic rabbits. Congress of the International Association for Biological Standards-Cytokines. LondonEngland 1987
   Google Scholar
• Deem R L, Shananan F, Targan SR. Triggered human mucosal T cells release tumor necrosis factor-alpha and interferon-gamma which kill human colonic epithelial cells. Clin Exp Immunol 1991; 83: 79–84
   PubMed Web of Science ®Google Scholar
• Cantrell D A, Smith KA. The interleukin-2 T-cell system. Science 1984; 224: 1312–6
   PubMed Web of Science ®Google Scholar
• Ruscetti F W, Gallo RC. Human T lymphocyte growth factor: regulation of growth and function of T lymphocytes. Blood 1981; 57: 379–94
   PubMed Web of Science ®Google Scholar
• Ebert E C, Wright S C, Lipshutz W H, Haupman SP. T cell abnormalities in inflammatory bowel diseases are mediated by interleukin 2. Clin Immunol Immunopathol 1984; 33: 232–44
   PubMedGoogle Scholar
• Fiocchi C. Lymphokines and the intestinal immune response. Role in inflammatory bowel disease. Immunol Invest 1989; 18: 91–102
   PubMed Web of Science ®Google Scholar
• Kusugami K, Matsuura T, West G A, Youngman K R, Rachmilewitz D, Fiocchi C. Loss of interleukin-2-producing intestinal CD4+ T cells in inflammatory bowel disease. Gastroenterology 1991; 101: 1594–1605
   PubMed Web of Science ®Google Scholar
• Fiocchi C, Hilfiker M L, Youngman K R, Doerder N C, Finke JH. Interleukin 2 activity of human intestinal mucosa mononuclear cells. Decreased levels in inflammatory bowel disease. Gastroenterology 1984; 86: 734–42
   PubMed Web of Science ®Google Scholar
• Fiocchi C, Tubbs R, Youngman KR. Human intestinal mucosal mononuclear cells exhibit lymphokine-activated killer cell activity. Gastroenterology 1985; 88: 625–37
   PubMed Web of Science ®Google Scholar
• Manzano L, Alvarez-Mon M, Abreu L. Functional impairment of natural killer cells in active ulcerative colitis: revision of the defective natural killer activity by interleukin 2. Gut 1992; 33: 246–51
   PubMedGoogle Scholar
• James SP. Remission of Crohn's disease after human immunodeficiency virus infection. Gastroenterology 1988; 96: 1667–9
   Google Scholar
• Miyasaka N, Nakarama T, Russell I J, Talal N. Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol 1984; 31: 109–17
   PubMedGoogle Scholar
• Davidsen B. Concanavalin A induced suppressor activity exerted by peripheral blood mononuclear cells-with special reference to chronic inflammatory bowel disease. Dan Med Bull 1988; 35: 201–22
   PubMedGoogle Scholar
• Selby W S, Janossy G, Bonfill M, Jewell DP. Intestinal lymphocyte subpopulation in inflammatory bowel disease: An analysis by immunohistological and cell isolation techniques. Gut 1984; 25: 32–40
   PubMed Web of Science ®Google Scholar
• James S P, Fiocchi C, Graeff A S, Strober W. Immunoregulatory functions of lamina propria T in Crohn's disease. Gastroenterology 1985; 88: 1143–50
   PubMed Web of Science ®Google Scholar
• Cornaby A, Simpson M A, Vannrice R. Dempsey RA, Madras PN, Monaco AP. Interleukin-2 production in plasma and urine, plasma interleukin-2 receptor levels, and urine cytology as a means of monitoring renal allograft recipients. Transplant Proc 1988; 20: 108–10, Suppl 1
   Web of Science ®Google Scholar
• Sunder-Plassmann G, Stockenhuber F, Balcke O. Serum interleukin 2 activity in renal graft recipients. Transplant Proc 1988; 20: 387–9
   PubMedGoogle Scholar
• Trotter J L, Clifford D B, Anderson C B, Van der Veen R C, Hicks B C, Banks G. Elevated serum interleukin-2 levels in chronic progressive multiple sclerosis. N Engl J Med 1988; 322: 1206
   Google Scholar
• Wolf R E, Baethge BA. lnterleukin-lα, interleukin-2, and soluble interleukin-2 receptors in polymyositis. Arthritis Rheum 1990; 33: 1007–14
   PubMedGoogle Scholar
• Brynskov J, Tvede N. Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin. Gut 1990; 31: 795–9
   PubMed Web of Science ®Google Scholar
• James S P, Mullin GE. Lymphokine production by mucosal T cells in inflammatory bowel disease. Inflammatory bowel disease. Progress in basic research and clinical implication, H Goebell, K Ewe, H Malchow, CH Koeibel. Kluwer Academic Publishers, Dordrecht 1991; 71–81
   Google Scholar
• Fujii M, Sogamura K, Sabno K, Nakai M, Sugita K, Hinuma Y. High-affinity receptor-mediated internalization and degradation of interleukin 2 in human T-cells. J Exp Med 1986; 163: 550–62
   PubMed Web of Science ®Google Scholar
• Sharon M, Klausner R D, Cullen B R, Chizzonite R, Leonard WJ. Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science 1986; 23: 859–63
   Google Scholar
• Teshigawara K, Wang H, Kato K, Smith KA. Interleukin 2 high-affinity receptor expression requires two distinct binding proteins. J Exp Med 1986; 165: 223–38
   Google Scholar
• Tsudo M, Kozak R W, Goldman C K, Waldman TA. Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in multichain interleukin 2 receptor complex. Proc Natl Acad Sci 1986; 83: 9694–8
   PubMed Web of Science ®Google Scholar
• Forsythe J L, Shenton B K, Parrot N R, Taylor R M, Proud G. Plasma interleukin 2 receptor levels in renal allograft dysfunction. Transplantation 1989; 48: 155–7
   PubMedGoogle Scholar
• Adam D H, Hubscher S G, Wang L, Elisa E. Soluble interleukin-2 receptors in serum and bile of liver transplant recipients. Lancet 1989; 1: 469–71
   PubMedGoogle Scholar
• Marcon L, Fritz M E, Kurman C C, Jensen J C, Nelson DL. Soluble Tac peptide is present in the urine of normal individuals and at elevated levels in patients with adult T cell leukaemia (ATL). Clin Exp Immunol 1988; 73: 29–33
   PubMed Web of Science ®Google Scholar
• Lobo-Yeo A, Mieli-Verganis G, Mowat A P, Verganis D. Soluble interleukin 2 receptors in autoimmune chronic active hepatitis. Gut 1990; 31: 690–3
   PubMedGoogle Scholar
• Wolf R E, Brelsford WG. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum 1988; 31: 729–35
   PubMed Web of Science ®Google Scholar
• Crabtree J E, Juby L D, Heatley R V, Lobo A J, Bullimore D W, Axon A TR. Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity. Gut 1990; 31: 1033–6
   PubMed Web of Science ®Google Scholar
• Mahida Y R, Gallagher A, Kurlac L, Hawkey CJ. Circulating and tissue interleukin 2 receptor levels in inflammatory bowel disease. Clin Exp Immunol 1990; 82: 75–80
   PubMedGoogle Scholar
• Mueller C, Knoflach P, Zielinski CC. T-cell activation in Crohn's disease. Increased levels of soluble interleukin 2 receptor in serum and in supernatants of stimulated peripheral blood mononuclear cells. Gastroenterology 1990; 98: 639–46
   PubMed Web of Science ®Google Scholar
• Mahida Y R, Patel S, Wu K, Jewell DP. Interleukin-2 receptor expression by macrophages in inflammatory bowel disease. Clin Exp Immunol 1988; 74: 382–6
   PubMedGoogle Scholar
• Pallone F, Fais S, Squarcia O, Biancone L, Pozzilli P, Biorivant M. Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. Gut 1990; 28: 745–53
   Google Scholar
• Raedler A, Schreiber S. Immunology of ulcerative colitis. Hepatogastroentcrology 1989; 36: 213–8
   PubMedGoogle Scholar
• Malizia G, Calabrese A, Cottone M. Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease. Gastroenterology 1991; 100: 150–9
   PubMed Web of Science ®Google Scholar
• Waldmann T A, Goldman C K, Robb R J. Expression of interleukin-2 receptors in activated B cells. J Exp Med 1984; 160: 1450–66
   PubMed Web of Science ®Google Scholar
• Schreiber S, Raedler A, Conn A R, Rombeau J L, MacDermott RP. Increased in vitro release of soluble interleukin 2 receptors by colonic lamina propria mononuclear cells in inflammatory bowel disease. Gut 1992; 33: 23644
   Google Scholar
• Rubin L A, Jay G, Nelson DL. The released interleukin 2 receptor binds interleukin 2 efficiently. J Immunol 1986; 137: 3841–4
   PubMed Web of Science ®Google Scholar
• Bendtzen K. Clinical significance of cytokines. Natural and therapeutic regulation. Sem Clin Immunol 1991; 3: 5–13
   PubMedGoogle Scholar
• Snick J. Interleukin-6: an overview. Ann Rev Immunol 1990; 8: 253–78
   PubMed Web of Science ®Google Scholar
• Andus T, Gross V, Casar I. Activation of monocytes during inflammatory bowel disease. Pathobiology 1991; 59: 166–70
   PubMedGoogle Scholar
• Mitsuyama K, Sata M, Tanikawa K. Significance of interleukin-6 in patients with inflammatory bowel disease. Gastroenterol Jpn 1991; 26: 20–8
   PubMedGoogle Scholar
• Suzuki Y, Saito H, Kasanuki J, Kishimoto T, Tamura Y, Yoshida S. Significant increase of interleukin 6-production in blood mononuclear leukocytes obtained from patients with active inflammatory bowel disease. Life Sci 1990; 47: 2193–7
   PubMed Web of Science ®Google Scholar
• Mahida Y R, Kurlac L, Gallagher A, Hawkey CJ. High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. Gut 1991; 32: 1531–4
   PubMed Web of Science ®Google Scholar
• Gross V, Andus T, Caesar J, Roth M, Scholmerich J. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992; 102: 514–9
   PubMed Web of Science ®Google Scholar
• Nielsen OH. In vitro studies on the significance of arachidonate metabolism and other oxidative processes in the inflammatory response of human neutrophils and macrophages with special reference to chronic inflammatory bowel disease. Scand J Gastroenterol 1988; 23: 1–21, Suppl 150
   PubMed Web of Science ®Google Scholar
• Sherry B, Cerami A. Small cytokine superfamily. Cur Opin lmmunol 1991; 3: 5660
   Google Scholar
• Matsushima K, Morishita K, Yoshimura T. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med 1988; 167: 1883–93
   PubMed Web of Science ®Google Scholar
• Oppenheim J J, Zachariae C OC, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene ‘intercrine’ cytokine family. Ann Rev Immunol 1991; 9: 617–48
   PubMed Web of Science ®Google Scholar
• Mahida Y R, Ceska M, Lindley I, Hawkey CJ. Increased mucosal interleukin 8 (NAP-1) in active ulcerative colitis [abstract]. Gastroenterology 1991; 100: A595
   Google Scholar
• Djeu J Y, Matsushima K, Oppenheim J J, Shiotsuki K, Blanchard DK. Functional activation of human neutrophils by recombinant monocyte-derived neutrophil chemotactic factor/ IL-8. J Immunol 1990; 144: 2205–10
   PubMed Web of Science ®Google Scholar
• Matsushima K, Oppenheim JJ. Interleukin 8 and MCAF novel inflammatory cytokines inducible by IL 1 and TNF. Cytokine 1989; 1: 2–13
   PubMedGoogle Scholar
• Schroeder JM. The monocyte-derived neutrophil activating peptide (NAP-l/interleukin 8) stimulates human neutrophil arachidonate-5-lipoxygenase but not the release of cellular arachidonate. J Exp Med 1989; 170: 847–63
   PubMedGoogle Scholar
• Thelen M, Peveri P, Kernen P, Von Tscharner V, Wlaz A, Baggiolini M. Mechanism of neutrophil activation by NAF, a novel monocyte-derived peptide agonist. FASEB J 1988; 2: 27026
   Google Scholar
• Dunham I, Sargent C A, Trowsdale J, Cambell RD. Molecular mapping of the human major histocompatibility complex by pulsed-field gel electrophoresis. Proc Natl Acad Sci 1987; 84: 7237–41
   PubMed Web of Science ®Google Scholar
• Ragoussis I, Bloemer K, Weiss E H, Ziegler A. Localization of the genes for tumor necrosis factor and lymphotoxih between the HLA class I and III regions by field inversion gel electrophoresis. Immunogenetics 1988; 27: 66–9
   PubMedGoogle Scholar
• Bendtzen K, Morling N, Fomsgaard A. Association between HLA-D2R and production of tumor necrosis factor α and interleukin 1 by mononuclear cells activated by pipopolysaccharide. Scand J Immunol 1988; 28: 599–606
   PubMed Web of Science ®Google Scholar
• Fugger L, Bendtzen K, Morling N, Ryder L, Svejgaard A. Possible correlation of TNFa-production with RFLP in humans. Eur J Haematol 1989; 43: 255–6
   PubMedGoogle Scholar
• Jacob C O, Lewis G D, McDevitt HO. MHC class 11-associated variation in the production of tumor necrosis factor in mice and humans: relevance to the pathogenesis of autoimmune disease. Immunol Res 1991; 10: 156–68
   PubMed Web of Science ®Google Scholar
• Ellis A, McKay J, Woodrow J C, McConnell RB. Tissue antigens and inflammatory bowel disease. Front Gastroent Res 1986; 11: 35–41
   Google Scholar
• Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316: 379–85
   PubMed Web of Science ®Google Scholar
• Bendtzen K. Why is too little TNF bad. Cytokine 1991; 3: 636–7
   PubMedGoogle Scholar
• Hyams J S, Treem W R, Eddy E, Wyzga N, Moore RE. Tumor necrosis factor-α is not elevated in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1991; 12: 233–6
   PubMed Web of Science ®Google Scholar
• Murch S H, Lamkin V A, Savage M O, Walker-Smith J A, Mac-Donald TT. Serum concentrations of tumor necrosis factor α in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913–7
   PubMed Web of Science ®Google Scholar
• Braegger C P, Nicholls S, Murch S H, Stephens S, MacDonald TT. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89–91
   PubMed Web of Science ®Google Scholar
• Fais S, Capobianchi M R, Pallone F. Spontaneous release of interferon γ by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon γ inducers. Gut 1991; 32: 403–7
   PubMed Web of Science ®Google Scholar
• MacDonald T T, Hutchings P, Choy M-Y, Murch S, Cooke A. Tumor necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990; 81: 301–5
   PubMed Web of Science ®Google Scholar
• Lieberman B Y, Fiocchi C, Youngman K R, Sapatnekar W K, Proffitt MR. Interferon γ production by human intestinal mucosal cells: decreased levels in inflammatory bowel disease. Dig Dis Sci 1988; 33: 1297–1304
   PubMed Web of Science ®Google Scholar
• Fiocchi C. Lymphokines and the intestinal immune response. Role in inflammatory bowel disease. Immunol Invest 1989; 18: 91–102
   PubMed Web of Science ®Google Scholar
• Mahida Y R, Lamming C ED, Gallagher A, Hawthorne A B, Hawkey CJ. 5-aminosalicylic acid is a potent inhibitor of interleukin 1β production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 1991; 32: 50–4
   PubMed Web of Science ®Google Scholar
• Remvig L, Anderson B. Salicylazosulfapyridine effect on endotoxin-induced production of interleukin-1-like factor from human monocytes in vitro. Scand J Rheumatol 1990; 19: 114
   Google Scholar
• Fujiwara M, Mitsui K, Yamamoto I. Inhibition of proliferative responses and interleukin 2 productions by salazosulfapyridine and its metabolites. Jpn J Pharmacol 1990; 54: 121–31
   PubMedGoogle Scholar
• Shanahan F, Niederlehner A, Carramanzana N, Anton P. Sulfasalazine inhibits the binding of TNFa to its receptor. Immunopharmacology 1990; 20: 217–24
   PubMed Web of Science ®Google Scholar
• Cominelli F, Zipser R D, Dinarello CA. Sulfasalazine inhibits cytokine production in human mononuclear cells: a novel antiinflammatory mechanism. Gastroenterology 1988; 96: A96
   Google Scholar
• Beato M, Briiggemeier U, Chalepakis G. Regulation of transcription by glucucorticoids. The hormonal control of gene transcription, P Cohen, JG Foulkes. Elsevier Science Publishers B.V., Amsterdam 1991; 117–28
   Google Scholar
• DiRosa M, Flower R J, Hirata F, Parente L, Russo-Marie F. Antiphospholipase proteins. Prostaglandins 1984; 28: 441–2
   PubMedGoogle Scholar
• Werb Z, Foley R, Munck A. Interation of glucocorticoids with macrophages. Identification of glucocorticoid receptors in monocytes and macrophages. J Exp Med 1978; 147: 1684–93
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Petersen J. Effects of cyclosporin A (CyA) and methylprednisolone (MP) on the immune response. I. T cell-activating factor (IL-1) abrogates CyA-but not MP-induced suppression of antigen-induced lymphokine production. Immunol Lett 1982; 5: 79–83
   PubMedGoogle Scholar
• Lew W, Oppenheim J J, Matsushima K. Analysis of the suppression of IL-lα and IL-1β production in human peripheral blood mononuclear adherent cells by a glucocorticoid hormone. J Immunol 1988; 140: 1895–2
   PubMed Web of Science ®Google Scholar
• Horst H J, Flad HD. Corticosteroid-interleukin 2 interactions: inhibition of binding of interleukin 2 to interleukin 2 receptors. Clin Exp Immunol 1987; 68: 151–61
   Google Scholar
• Goodwin J S, Atluru D, Sierakowski S, Lianos EA. Mechanism of action of glucocorticoids. Inhibition of T cell proliferation and interleukin 2 production of hydrocortisone is reversed by leukotriene B4. J Clin Invest 1986; 77: 1244–50
   PubMed Web of Science ®Google Scholar
• Arya S K, Wong-Staal F, Gallo RC. Dexamethasone-mediated inhibition of human T cell growth factor and gamma interferon messenger RNA. J Immunol 1984; 133: 273–6
   PubMed Web of Science ®Google Scholar
• Mokoena T, Gordon S. Human macrophage activation. Modulation of mannosyl, fucosyl receptor activity in vitro by lymphokines, gamma and alpha interferons, and dexamethasone. J Clin Invest 1985; 75: 624–31
   PubMed Web of Science ®Google Scholar
• Culpepper J A, Lee F. Regulation of IL-3 expression by glucocorticoids in cloned murine T lymphocytes. J Immunol 1985; 135: 3191–7
   PubMed Web of Science ®Google Scholar
• Wallen N, Kita H, Weiler D, Gleich GJ. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 1991; 147: 3490–5
   PubMed Web of Science ®Google Scholar
• Andus T, Gross V, Casar I, Krumm D, Hosp J, David M, Scholmerich J. Activation of monocytes during inflammatory bowel disease. Pathobiology 1991; 59: 166–70
   PubMedGoogle Scholar
• Mukaida N, Shiro M, Matsushima K. Genomic structure of the human monocyte-derived neutrophil chemotactic factor interleukin 8. J Immunol 1989; 143: 1366–71
   PubMed Web of Science ®Google Scholar
• Harding M W, Galat A, Uehling D E, Schreiber SL. A receptor for the immunosuppressant FK.506 is a cis-trans peptidyi-prolyl isomerase. Nature 1989; 341: 758–60
   PubMed Web of Science ®Google Scholar
• Siekierka J J, Hung S HY, Poe M. Lin CS Sigal NJ. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989; 341: 755–7
   PubMed Web of Science ®Google Scholar
• Elliot J F, Lin Y, Mizel S B, Bleackley R C, Harnish D G, Laetkau V. Induction of interleukin 2 messenger RNA inhibited by cyclosporin A. Science 1984; 226: 1439–41
   PubMed Web of Science ®Google Scholar
• Bunjes D, Hardt C, Rollinghoff M, Wagner H. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol 1981; 11: 657–61
   PubMed Web of Science ®Google Scholar
• Kalman V K, Klimpel GR. Cyclosporin A inhibits the production of γ interferon but does not inhibit production of virus induced IFN α/β. Cell Immunol 1983; 78: 122–9
   PubMedGoogle Scholar
• Wasik M A, Beller DI. Induction of macrophage membrane interleukin 1 expression by T-cell dependent and T-cell independent pathways is inhibited by cyclosporin A. Clin Immunol Immunopathol 1989; 52: 331–40
   PubMedGoogle Scholar
• Kupiec-Weglinski J W, Filho M A, Strom T B, Tihey BL. Sparing of suppressor cells: a critical action of cyclosporine. Transplantation 1984; 38: 97–101
   PubMedGoogle Scholar
• Evans C M, Philips A D, Walker-Smith J A, MacDonald TT. Activation of lamina propria T cells induces crypt epithelial proliferation and goblet cell depletion in cultured human fetal colon. Gut 1992; 33: 230–5
   PubMedGoogle Scholar
• Hess A D, Colombani PM. Cyclosporin A. Mechanism of action (in vitro studies). Progr Allergy 1986; 38: 198–221
   PubMedGoogle Scholar
• Knudsen P J, Dinarello C A, Strom TB. Prostaglandins post-transcriptionally inhibit monocyte expression of interleukin-1 activity by increasing intracellular cyclic adenosine mono-phosphate. J Immunol 1986; 137: 3189–94
   PubMed Web of Science ®Google Scholar
• Monick M, Glazier J, Hunninghake GW. Human alveolar macrophages suppress interleukin-1 (IL-1) activity via the secretion of prostaglandin E2. Am Rev Respir Dis 1987; 135: 72–7
   PubMed Web of Science ®Google Scholar
• Sato I Y, Kobayashi K, Yamagata N. Modulation of granuloma formation in vitro by endogenous mediators. Immunopharmacol 1991; 21: 73–82
   PubMedGoogle Scholar
• Haynes D R, Wright P F, Whitehouse M W, Vernon-Roberts B. The cyclo-oxygenase inhibitor, piroxicam, enhances cytokine-induced lymphocyte proliferation in vitro and in vivo. Immunol Cell Biol 1990; 68: 225–30
   PubMedGoogle Scholar
• Dinarello CA. Interleukin-1 and other growth factors. Textbook of rheumatology, WN Kelly, ED Harris, S Ruddy, CB Sledge. W.B. Saunders Company, Philadelphia 1989; 285–99
   Google Scholar
• Baker P E, Fahey J V, Munck A. Prostaglandin inhibition of T cell proliferation is mediated at two levels. Cell Immunol 1981; 61: 52–61
   PubMed Web of Science ®Google Scholar
• Rappaport R H, Dodge DR. Prostaglandin E inhibits the production of human interleukin 2. J Exp Med 1982; 155: 943–8
   PubMed Web of Science ®Google Scholar
• Browning J L, Ribolini A. Interferon blocks interleukin 1-induced prostaglandin release from human peripheral monocytes. J Immunol 1987; 138: 2857–63
   PubMedGoogle Scholar
• Hart P H, Vitti G F, Burgess D R, Whitty G A, Piccoli D S, Hamilton JA. Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin-1 a, d prostaglandin E2. Proc Natl Acad Sci 1989; 86: 3803–7
   PubMed Web of Science ®Google Scholar
• Henderson B, Pettipher ER. Comparison of the in vivo inflammatory activities after intra-articular injection of natural and recombinent IL-1 alpha and IL-1 beta in the rabbit. Biochem Pharmacol 1988; 37: 4171–6
   PubMedGoogle Scholar
• Hellerstein M K, Meydani S N, Meydani M, Wu K, Dinarello CA. Interleukin-1-induced anorexia in the rat. Influence of prostaglandins. J Clin Invest 1989; 84: 228–35
   PubMed Web of Science ®Google Scholar
• Boraschi D, Villa L, Volpini G, Bossu P, Censini S, Ghiara P. Differential activity of interleukin 1 alpha and interleukin 1 beta in the stimulation of the immune response in vivo. Eur J Immunol 1990; 20: 317–21
   PubMed Web of Science ®Google Scholar
• Hauptmann B, VanDamme J, Dayer JM. Modulation of IL-1 inflammatory and immunornodulatory properties by IL-6. Eur Cytokine Netw 1991; 2: 39–46
   PubMedGoogle Scholar
• Ferrandiz M I, Foster SJ. Tumour necrosis factor production in a rat airpouch model of inflammation: role of eicosanoids. Agents Actions 1991; 32: 289–94
   PubMedGoogle Scholar
• Kirstein D, Thomsen M K, Ahnfelt-Rbnne I. Inhibition of leukotriene biosynthesis and polymorphonuclear leukocyte functions by orally active quinolylmethoxyphenylamines. Pharmacol Toxicol 1991; 68: 125–30
   PubMedGoogle Scholar
• Marshall P J, Griswold D E, Breton J, Webb E F, Hillegas L M, Sarau HM. Pharmacology of the pyrroloimidazole, SF & F 105809. I. Inhibition of inflammatory cytokine production and of 5-lipoxygenase and cyclooxygenase-mediated metabolism of arachidonic acid. Biochem Pharmacol 1991; 42: 813–24
   PubMedGoogle Scholar
• Rekonen R, Ustinov J. Interferon-gamma augments hydrolysis of LTA4 to LTB4 by endothelial cells. Prostaglandins 1990; 39: 205–11
   PubMedGoogle Scholar
• Merrill J P, Strom S R, Ellison G W, Myers LW. In vitro study of mediators of inflammation in multiple sclerosis. J Clin Immunol 1989; 9: 84–96
   PubMed Web of Science ®Google Scholar
• Maloff B L, Shaw J E, Di-Meo TM. IL-1 dependent model of inflammation mediated by neutrophils. J Pharmacol Meth 1989; 22: 133–40
   PubMedGoogle Scholar
• Rubin R M, Rosenbaum JT. A platelet-activating factor antagonist inhibits interleukin 1-induced inflammation. Biochem Biophys Res Commun 1988; 154: 429–36
   PubMedGoogle Scholar
• Rola-Pleszczynski M, Stankova J. Cytokine gene regulation by PGE2, LTB, and PAF. Med Inflam 1992; 1: 5–8
   PubMedGoogle Scholar
• Ward P A, Warren J S, Johnson KJ. Oxygen radicals, inflammation, and tissue injury. Free Radic Biol Med 1988; 5: 403–8
   PubMed Web of Science ®Google Scholar